Exelixis, Inc. (0IJO.L)
USD 34.24
(-1.28%)
USD 34.24
(-1.28%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 170.88 Million USD | -15.19% |
| 2022 | 201.48 Million USD | -29.71% |
| 2021 | 286.66 Million USD | 160.46% |
| 2020 | 110.06 Million USD | -70.21% |
| 2019 | 369.47 Million USD | -15.81% |
| 2018 | 438.85 Million USD | 164.51% |
| 2017 | 165.91 Million USD | 689.92% |
| 2016 | -28.12 Million USD | 76.84% |
| 2015 | -121.42 Million USD | 45.9% |
| 2014 | -224.45 Million USD | -11.82% |
| 2013 | -200.73 Million USD | -63.95% |
| 2012 | -122.43 Million USD | -236.75% |
| 2011 | 89.53 Million USD | 197.96% |
| 2010 | -91.39 Million USD | 25.03% |
| 2009 | -121.9 Million USD | 32.01% |
| 2008 | -179.31 Million USD | -14.18% |
| 2007 | -157.04 Million USD | -23.9% |
| 2006 | -126.75 Million USD | -34.86% |
| 2005 | -93.99 Million USD | 30.48% |
| 2004 | -135.2 Million USD | -40.46% |
| 2003 | -96.25 Million USD | -9.6% |
| 2002 | -87.82 Million USD | -16.61% |
| 2001 | -75.31 Million USD | -75.7% |
| 2000 | -42.86 Million USD | -128.0% |
| 1999 | -18.8 Million USD | -22.91% |
| 1998 | -15.29 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 276.34 Million USD | 837.98% |
| 2024 Q3 | 136.07 Million USD | -50.76% |
| 2024 Q1 | 29.46 Million USD | -63.98% |
| 2023 FY | 170.88 Million USD | -15.19% |
| 2023 Q3 | -17.58 Million USD | -122.59% |
| 2023 Q2 | 77.85 Million USD | 254.27% |
| 2023 Q1 | 21.97 Million USD | 145.71% |
| 2023 Q4 | 81.78 Million USD | 565.15% |
| 2022 Q2 | 83.7 Million USD | -3.84% |
| 2022 Q1 | 87.05 Million USD | -25.37% |
| 2022 Q3 | 82.61 Million USD | -1.31% |
| 2022 Q4 | -48.07 Million USD | -158.2% |
| 2022 FY | 201.48 Million USD | -29.71% |
| 2021 FY | 286.66 Million USD | 160.46% |
| 2021 Q1 | -4.6 Million USD | -118.96% |
| 2021 Q2 | 123 Million USD | 2770.02% |
| 2021 Q4 | 116.64 Million USD | 125.96% |
| 2021 Q3 | 51.62 Million USD | -58.03% |
| 2020 Q2 | 75.53 Million USD | 43.03% |
| 2020 Q3 | -42.58 Million USD | -156.37% |
| 2020 Q4 | 24.29 Million USD | 157.06% |
| 2020 FY | 110.06 Million USD | -70.21% |
| 2020 Q1 | 52.8 Million USD | -31.7% |
| 2019 Q1 | 84.55 Million USD | -24.23% |
| 2019 FY | 369.47 Million USD | -15.81% |
| 2019 Q4 | 77.31 Million USD | -33.12% |
| 2019 Q3 | 115.6 Million USD | 25.67% |
| 2019 Q2 | 91.98 Million USD | 8.79% |
| 2018 Q1 | 116.3 Million USD | 210.72% |
| 2018 FY | 438.85 Million USD | 164.51% |
| 2018 Q4 | 111.6 Million USD | -10.84% |
| 2018 Q3 | 125.17 Million USD | 45.94% |
| 2018 Q2 | 85.77 Million USD | -26.26% |
| 2017 Q4 | 37.43 Million USD | -53.89% |
| 2017 Q1 | 20.18 Million USD | -48.09% |
| 2017 FY | 165.91 Million USD | 689.92% |
| 2017 Q3 | 81.18 Million USD | 199.41% |
| 2017 Q2 | 27.11 Million USD | 34.32% |
| 2016 Q3 | 7.26 Million USD | 128.9% |
| 2016 Q1 | -49.13 Million USD | -55.49% |
| 2016 FY | -28.12 Million USD | 76.84% |
| 2016 Q4 | 38.88 Million USD | 435.28% |
| 2016 Q2 | -25.13 Million USD | 48.84% |
| 2015 Q2 | -31.28 Million USD | -37.43% |
| 2015 FY | -121.42 Million USD | 45.9% |
| 2015 Q4 | -31.6 Million USD | 11.68% |
| 2015 Q3 | -35.78 Million USD | -14.39% |
| 2015 Q1 | -22.76 Million USD | 50.74% |
| 2014 FY | -224.45 Million USD | -11.82% |
| 2014 Q4 | -46.2 Million USD | 10.4% |
| 2014 Q3 | -51.57 Million USD | 16.4% |
| 2014 Q2 | -61.68 Million USD | 5.08% |
| 2014 Q1 | -64.98 Million USD | -9.2% |
| 2013 FY | -200.73 Million USD | -63.95% |
| 2013 Q4 | -59.51 Million USD | -6.44% |
| 2013 Q3 | -55.91 Million USD | -9.0% |
| 2013 Q2 | -51.29 Million USD | -50.82% |
| 2013 Q1 | -34.01 Million USD | 18.97% |
| 2012 Q4 | -41.97 Million USD | -64.97% |
| 2012 FY | -122.43 Million USD | -236.75% |
| 2012 Q1 | -22.29 Million USD | -143.23% |
| 2012 Q2 | -32.72 Million USD | -46.77% |
| 2012 Q3 | -25.44 Million USD | 22.25% |
| 2011 Q4 | 51.57 Million USD | -35.29% |
| 2011 FY | 89.53 Million USD | 197.96% |
| 2011 Q3 | 79.69 Million USD | 542.58% |
| 2011 Q2 | -18 Million USD | 24.11% |
| 2011 Q1 | -23.73 Million USD | -68.18% |
| 2010 Q2 | -25.63 Million USD | 45.99% |
| 2010 Q4 | -14.11 Million USD | -235.55% |
| 2010 Q3 | -4.2 Million USD | 83.59% |
| 2010 Q1 | -47.45 Million USD | -56.59% |
| 2010 FY | -91.39 Million USD | 25.03% |
| 2009 Q1 | -36.77 Million USD | 6.43% |
| 2009 Q4 | -30.3 Million USD | -80.19% |
| 2009 Q3 | -16.81 Million USD | 55.76% |
| 2009 Q2 | -38.01 Million USD | -3.37% |
| 2009 FY | -121.9 Million USD | 32.01% |
| 2008 Q2 | -48.68 Million USD | -4.21% |
| 2008 Q1 | -46.72 Million USD | -9.26% |
| 2008 FY | -179.31 Million USD | -14.18% |
| 2008 Q4 | -39.3 Million USD | 11.89% |
| 2008 Q3 | -44.6 Million USD | 8.38% |
| 2007 Q4 | -42.76 Million USD | -0.32% |
| 2007 Q2 | -38.3 Million USD | -14.82% |
| 2007 Q1 | -33.35 Million USD | 1.17% |
| 2007 FY | -157.04 Million USD | -23.9% |
| 2007 Q3 | -42.62 Million USD | -11.29% |
| 2006 Q1 | -31.05 Million USD | -5.29% |
| 2006 Q4 | -33.75 Million USD | -6.95% |
| 2006 Q3 | -31.56 Million USD | -3.88% |
| 2006 Q2 | -30.38 Million USD | 2.17% |
| 2006 FY | -126.75 Million USD | -34.86% |
| 2005 Q3 | -27.89 Million USD | -189.28% |
| 2005 Q1 | -26.96 Million USD | 47.23% |
| 2005 Q4 | -29.49 Million USD | -5.75% |
| 2005 FY | -93.99 Million USD | 30.48% |
| 2005 Q2 | -9.64 Million USD | 64.24% |
| 2004 Q3 | -26.63 Million USD | 7.7% |
| 2004 Q2 | -28.85 Million USD | -0.87% |
| 2004 FY | -135.2 Million USD | -40.46% |
| 2004 Q1 | -28.61 Million USD | -21.7% |
| 2004 Q4 | -51.09 Million USD | -91.81% |
| 2003 Q1 | -23.3 Million USD | -11.29% |
| 2003 Q2 | -24.31 Million USD | -4.33% |
| 2003 Q3 | -25.12 Million USD | -3.33% |
| 2003 FY | -96.25 Million USD | -9.6% |
| 2003 Q4 | -23.51 Million USD | 6.43% |
| 2002 Q1 | -19.9 Million USD | -6.17% |
| 2002 Q4 | -20.94 Million USD | 8.85% |
| 2002 FY | -87.82 Million USD | -16.61% |
| 2002 Q3 | -22.97 Million USD | 0.39% |
| 2002 Q2 | -23.06 Million USD | -15.89% |
| 2001 Q3 | -17.29 Million USD | 30.48% |
| 2001 Q2 | -24.87 Million USD | -72.88% |
| 2001 Q1 | -14.39 Million USD | -20.66% |
| 2001 Q4 | -18.74 Million USD | -8.4% |
| 2001 FY | -75.31 Million USD | -75.7% |
| 2000 Q4 | -11.92 Million USD | -8.55% |
| 2000 Q1 | -7.27 Million USD | 0.0% |
| 2000 Q2 | -12.67 Million USD | -74.11% |
| 2000 FY | -42.86 Million USD | -128.0% |
| 2000 Q3 | -10.98 Million USD | 13.28% |
| 1999 FY | -18.8 Million USD | -22.91% |
| 1998 FY | -15.29 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 201.007% |
| Dynavax Technologies Corporation | -37.02 Million USD | 561.502% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 3343.215% |
| Perrigo Company plc | 151.9 Million USD | -12.498% |
| Illumina, Inc. | -1.06 Billion USD | 115.986% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 97.509% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 137.104% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 101.214% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 91.356% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 254.486% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 95.778% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 482.576% |
| Waters Corporation | 817.67 Million USD | 79.101% |
| Biogen Inc. | 1.29 Billion USD | 86.823% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 162.366% |
| Evolus, Inc. | -49.23 Million USD | 447.094% |
| Adicet Bio, Inc. | -152.03 Million USD | 212.396% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 240.652% |
| bluebird bio, Inc. | -244.26 Million USD | 169.96% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 209.849% |
| FibroGen, Inc. | -281.81 Million USD | 160.637% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 87.342% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 479.093% |
| Homology Medicines, Inc. | -48.25 Million USD | 454.129% |
| Geron Corporation | -193.94 Million USD | 188.11% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 160.56% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 332.516% |
| Myriad Genetics, Inc. | -123.7 Million USD | 238.145% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 269.483% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 133.163% |
| Zoetis Inc. | 3.06 Billion USD | 94.432% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 454.533% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 84.283% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 12.115% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 96.033% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 536.454% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 148.309% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 161.914% |
| Verastem, Inc. | -92.08 Million USD | 285.575% |
| Nektar Therapeutics | -137.42 Million USD | 224.348% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 173.713% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 275.524% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 163.805% |
| OPKO Health, Inc. | -157.02 Million USD | 208.829% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 31.891% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -59.286% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 406.487% |
| uniQure N.V. | -282.87 Million USD | 160.411% |
| Imunon, Inc. | -21.03 Million USD | 912.561% |
| Blueprint Medicines Corporation | -486.27 Million USD | 135.141% |
| Insmed Incorporated | -709.62 Million USD | 124.081% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 49.379% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 143.65% |
| TG Therapeutics, Inc. | 20.63 Million USD | -728.212% |
| Incyte Corporation | 620.52 Million USD | 72.461% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 123.525% |